Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population
|
By LabMedica International staff writers Posted on 03 Dec 2021 |

The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests by physicians, low price of tests, and awareness about complications of high diabetes levels.
These are the latest findings of Transparency Market Research (Albany, NY, USA), a next-generation market intelligence provider.
The term HbA1c corresponds to glycated hemoglobin. HbA1c progresses when a protein hemoglobin present in red blood cells that transports oxygen throughout body joins with blood glucose, thereby becoming 'glycated’. This test is conducted on people with Type 1 and Type 2 diabetes. The normal range for HBA1c is less than 6%. They are also known as glycosylated or glycated hemoglobin. The measurement of HbA1c helps physicians to obtain a lucid picture of average blood sugar levels prevalent for a period of weeks/months
According to World Health Organization and International Diabetes Federation statistics, around 422 million people were suffering from diabetes in 2014. The global prevalence of diabetes has increased from 4.7% in 1980 to 8.5% in 2014. The global HBA1c laboratory tests market is expected to be driven by rise in diabetic population, increase in number of HBA1c laboratory tests, and technological advancements.
Additionally, a large number of employers across the world have introduced wellness programs, which ensure routine medical tests for employees in order to maintain overall productivity and resource efficiency. These initiatives, wherein an employee’s diagnostic tests and sometimes, even treatments are sponsored, have significantly increased the testing volume of clinical laboratories, thereby driving the market’s revenue. Moreover, such wellness programs play an important role in restoring the overall productivity in case of infectious diseases, which tend to affect a large number of people simultaneously.
North America is projected to account for a prominent share of the global HBA1c laboratory tests market over the coming years, led by an increase in awareness about these tests, high rate of adoption of HbA1c tests, owing to increased physicians prescriptions, and technological advancements in the US. Favorable reimbursement policies, increase in the number of laboratories for hemoglobin A1c testing, growth of diabetes among the geriatric population, and rise in funding by governments are anticipated to propel the growth of the North American HBA1c laboratory tests market. An increase in the number of patients with diabetes visiting hospitals and clinics and focus of new players on partnerships with laboratories will drive the US HBA1c laboratory tests market.
Related Links:
Transparency Market Research
Latest Industry News
- Integrated DNA Technologies Expands into Clinical Diagnostics
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read moreMolecular Diagnostics
view channel
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read more
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more








